Revolutionizing Breast Cancer Diagnosis with AI: The Story of Emna Bouassida and MediGenius
Today, AI is transforming our habits and expanding into all sectors, including medicine. At a young age, Emna Bouassida is revolutionizing breast cancer diagnosis with AI. She founded MediGenius, a pioneering company that develops an innovative software platform dedicated to the medical sector, leveraging advanced AI for its applications. At just 23 years old, the young researcher specializing in intelligent systems engineering has distinguished herself by winning the "Les Pépites de demain" award during the 8th edition of the Tunisia Women Entrepreneurs Program (FET), supported by Impact Partner. This success has propelled her solution forward, transforming the radiology landscape.
In our interview, she highlights the growing challenges faced by radiologists due to the increasing demand for medical imaging services. MediGenius, currently in development and already operational in Tunisia with a partnership established with a clinic in Sfax, focuses primarily on the private sector. This innovative solution, entirely based on artificial intelligence, assists radiologists in their clinical decisions, particularly for more accurate diagnoses, including early breast cancer detection.
"Our platform has enabled many women to benefit from a more accurate assessment of their breast health," she shares enthusiastically. Throughout her conversation, she also specifies that MediGenius offers an annual subscription starting from 45,000 Tunisian dinars, with a 30-day trial period, and adapts to the specific needs of users, including training and other essential services. To maximize the effectiveness of this strategy, Emna emphasizes the importance of a well-structured trial period, including effective onboarding, continuous support, and a clear strategy to facilitate the transition to a full subscription.
She also mentions that despite the current stage of development, international research on AI in radiology offers promising solutions in the short term and could potentially contribute to reducing breast cancer mortality in the long term. Is it possible to enter an era where AI could be used as a tool for curing diseases and potentially reducing mortality?
Soon, MediGenius will be presented at the Demo Day at the Hôtel Borj Dhiafa in Sfax on June 28th at 9 am. This step marks a new chapter for this promising company that aspires to transform medicine through technological innovation.
Finally, the young entrepreneur encourages everyone to keep hope and closely follow the future developments of MediGenius, an initiative that could redefine the field of medical radiology with its avant-garde approach and long-term vision.
MediGenius. Emna Bouassida, CEO of MediGenius.